Literature DB >> 24492888

FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants.

Nicholas Zalewski1, Hugo Botha, Jennifer L Whitwell, Val Lowe, Dennis W Dickson, Keith A Josephs.   

Abstract

The 4-repeat (4R)-tauopathies can be clinically heterogeneous and difficult to diagnose. An FDG-PET pattern of hypometabolism has been previously reported in clinically suspected 4R-tauopathies. Considering that pathological confirmation has not been used as inclusion criteria in these studies, however, the possibility exists that atypical cases were excluded. We studied pathologically confirmed cases of 4R-tauopathies to determine if FDG-PET patterns of hypometabolism different than those previously described exist. We identified all autopsy confirmed 4R-tauopathies with FDG-PET imaging performed between 2010 and 2013 within the Mayo Clinic database. Clinical features and FDG-PET imaging were compared to a group of normal controls. Ten patients, seven of which had autopsy-confirmed progressive supranuclear palsy (PSP), were identified. We also identified two cases with globular glial tauopathy (GGT) and one case of corticobasal degeneration (CBD). The overall predominant imaging findings included bilateral caudate hypometabolism in nine cases, mild asymmetric thalamic hypometabolism in eight, midbrain hypometabolism in seven, and bilateral hypometabolism in the supplementary motor area in seven. No differences were observed between PSP and GGT. The one CBD case had asymmetric parietal hypometabolism that was not seen in the PSP and GGT cases. As previously described, 4R-tauopathies are associated with frontal, caudate, midbrain and thalamic hypometabolism on FDG-PET. This is the first report of FDG-PET in GGT, and although our series was limited, no features distinguish GGT from PSP. There was some evidence that parietal hypometabolism may be suggestive of CBD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24492888     DOI: 10.1007/s00415-014-7256-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes.

Authors:  Ping Zhao; Benshu Zhang; Shuo Gao
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Globular glial tauopathies (GGT): consensus recommendations.

Authors:  Zeshan Ahmed; Gabor G Kovacs; Eileen H Bigio; Herbert Budka; Dennis W Dickson; Isidro Ferrer; Bernardino Ghetti; Giorgio Giaccone; Kimmo J Hatanpaa; Janice L Holton; Keith A Josephs; James Powers; Salvatore Spina; Hitoshi Takahashi; Charles L White; Tamas Revesz
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

3.  Corticobasal degeneration: neuropathologic and clinical heterogeneity.

Authors:  J A Schneider; R L Watts; M Gearing; R P Brewer; S S Mirra
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

4.  FDG PET in the differential diagnosis of parkinsonian disorders.

Authors:  Thomas Eckert; Anna Barnes; Vijay Dhawan; Steve Frucht; Mark F Gordon; Andrew S Feigin; D Eidelberg
Journal:  Neuroimage       Date:  2005-04-26       Impact factor: 6.556

5.  Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis.

Authors:  Rahyeong Juh; Chi-Un Pae; Tae-Suk Kim; Chang-Uk Lee; Boyoung Choe; Taesuk Suh
Journal:  Neurosci Lett       Date:  2005-04-21       Impact factor: 3.046

6.  The pimple sign of progressive supranuclear palsy syndrome.

Authors:  Hugo Botha; Jennifer L Whitwell; Ajay Madhaven; Matthew L Senjem; Val Lowe; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2013-11-04       Impact factor: 4.891

7.  Fluorodeoxyglucose positron emission tomography in Richardson’s syndrome and progressive supranuclear palsy-parkinsonism.

Authors:  Karin Srulijes; Matthias Reimold; Rajka M Liscic; Sarah Bauer; Elisabeth Dietzel; Inga Liepelt-Scarfone; Daniela Berg; Walter Maetzler
Journal:  Mov Disord       Date:  2012-01       Impact factor: 10.338

8.  Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech.

Authors:  Keith A Josephs; Joseph R Duffy; Edyth A Strand; Jennifer L Whitwell; Kenneth F Layton; Joseph E Parisi; Mary F Hauser; Robert J Witte; Bradley F Boeve; David S Knopman; Dennis W Dickson; Clifford R Jack; Ronald C Petersen
Journal:  Brain       Date:  2006-04-13       Impact factor: 13.501

9.  Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography.

Authors:  Madhavi Tripathi; Vijay Dhawan; Shichun Peng; Suman Kushwaha; Amit Batla; Abhinav Jaimini; Maria M D'Souza; Rajnish Sharma; Sanjiv Saw; Anupam Mondal
Journal:  Neuroradiology       Date:  2013-01-13       Impact factor: 2.804

10.  Cerebral glucose metabolism, clinical, neuropsychological, and radiological profile in patients with corticobasal syndrome.

Authors:  Surya Prabha Turaga; Rukmini Mridula; Rupam Borgohain
Journal:  Neurol India       Date:  2013 Jan-Feb       Impact factor: 2.117

View more
  19 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration.

Authors:  Katerina A Tetzloff; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Sarah M Boland; Rene L Utianski; Hugo Botha; Matthew L Senjem; Christopher G Schwarz; Keith A Josephs; Jennifer L Whitwell
Journal:  Neurocase       Date:  2018-05-25       Impact factor: 0.881

Review 3.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

Review 4.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

5.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Key emerging issues in progressive supranuclear palsy and corticobasal degeneration.

Authors:  Keith A Josephs
Journal:  J Neurol       Date:  2015-02-21       Impact factor: 4.849

7.  Prominent auditory deficits in primary progressive aphasia: A case study.

Authors:  Rene L Utianski; Joseph R Duffy; Heather M Clark; Mary M Machulda; Dennis W Dickson; Jennifer L Whitwell; Keith A Josephs
Journal:  Cortex       Date:  2019-02-21       Impact factor: 4.027

Review 8.  Recent Advancement and Clinical Implications of 18FDG-PET in Parkinson's Disease, Atypical Parkinsonisms, and Other Movement Disorders.

Authors:  Cecilia Peralta; Federico Biafore; Tamara Soto Depetris; Maria Bastianello
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-29       Impact factor: 5.081

Review 9.  Frontotemporal Dementias.

Authors:  Elizabeth C Finger
Journal:  Continuum (Minneap Minn)       Date:  2016-04

Review 10.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Authors:  Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs
Journal:  Mov Disord       Date:  2017-05-13       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.